GlassScriptPhysician profile
Dustin Briscoe
NPI 1407230774
$1,309.24
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $359 · 2020: $200 · 2021: $276 · 2022: $294 · 2023: $60.39 · 2024: $121.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $181.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $180.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $434.28 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $195.10 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $149.36 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $86.04 | 2022-2023 | Vyzulta, Prolensa, Lotemax Sm |
| Allergan, INC. | $66.47 | 2021-2022 | |
| Kala Pharmaceuticals, INC. | $50.27 | 2019-2021 | |
| Coopervision INC. | $50.00 | 2024 | Cvi Contact Lens |
| Glaukos Corporation | $39.28 | 2024 | Ce-Marked Kxla System |
| Oyster Point Pharma, INC. | $37.54 | 2022 | |
| Shire North American Group INC | $33.41 | 2019 | |
| Mallinckrodt Enterprises LLC | $32.31 | 2019 | |
| Abbvie INC. | $31.29 | 2024 | |
| Eyevance Pharmaceuticals LLC | $29.11 | 2021 | |
| Dompe US, INC. | $26.59 | 2022 | |
| Biotissue Holdings INC. | $26.42 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $21.77 | 2023 | Rocklatan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dustin Briscoe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.